Research and Markets: The CNS Pipeline Fact Book

Tue May 7, 2013 3:26pm EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: The CNS Pipeline Fact Book

Research and Markets ( has announced the addition of the "The CNS Pipeline Fact Book 2012" report to their offering.

The affordable desk reference for easily reviewing the state of the global CNS drug development landscape

The CNS pipeline is second only to cancer in terms of the number of pharmaceuticals in development. Espicom has looked at Phases I, II and III of the clinical development programme and has identified more than 270 agents. These include new chemical entities and biologicals, as well as novel formulations of known drugs and new indications for approved drugs in lifecycle development. While many more are in preclinical development, this report focuses on pharmaceuticals that have progressed to clinical studies in humans.

With this report you can instantly...

  • Know what drugs for Alzheimer's disease are in Phase II
  • Assess the CNS research portfolio for leading and emerging companies
  • Identify your research competitors and possible collaborators
  • Focus on companies who are targeting Multiple Sclerosis, and their status
  • Review drugs by specific routes of administration


  • CNS Clinical Pipeline Overview
  • Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Huntingdon's Disease
  • Duchenne's Muscular Dystrophy
  • Pain
  • Cancer Pain
  • Neuropathic Pain
  • Migraine
  • Osteoarthritis Pain
  • Other & Unspecified Pain Indications
  • Other CNS Indications
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Depression
  • Epilepsy
  • Schizophrenia
  • Sleep Disorders

For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System